Clinical trials: Proton Pump Inhibitor
HIV, Inhaled Corticosteroid
Optimizing Medications and Lung Health in People With HIV Through Pharmacist-led Proactive E-Consults
People with HIV (PWH) continue to experience elevated risk of community-acquired pneumonia despite effective antiretroviral therapy.
- Conditions
- HIV, Inhaled Corticosteroid, Proton Pump Inhibitor, Smoking Cessation
- Trial name
- NCT07507435
- Testing
- E-consult
- Where
- 3 sites in United States
- Volunteers
- 480 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Inappropriate Prescribing, Reflux Disease
Deprescribing Inappropriate Proton Pump Inhibitors
The DROPIT Trial is an interventional, open-labelled, cluster-randomized controlled trial conducted in the Swiss primary care setting.
- Conditions
- Inappropriate Prescribing, Reflux Disease, Proton Pump Inhibitors
- Trial name
- DROPIT (NCT06129474)
- Testing
- Proton Pump Inhibitor deprescribing tool
- Where
- 2 sites in Switzerland
- Volunteers
- 400 people
- Sponsor
- University of Bern
Upper GI Bleeding, Proton Pump Inhibitors
PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers
Vonoprazan (VPZ), an oral potassium-competitive acid blocker (P-CAB) has emerged as an alternative potent acid-suppressant.It has a faster onset of action in 1 day (3-5 days in PPI), and is more stable in acidic condition than…
- Trial name
- NCT05582174
- Testing
- Vonoprazan, esomeprazole
- Where
- 8 sites in China
- Volunteers
- 594 people
- Sponsor
- Chinese University of Hong Kong
Potassium-Competitive Acid Blocker, Proton Pump Inhibitor
Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection
This study aims to compare the eradication rate, safety, and patient adherence between potassium-competitive acid blockers (P-CABs) and proton pump inhibitor-based bismuth quadruple therapy in patients with Helicobacter pylori…
- Conditions
- Potassium-Competitive Acid Blocker, Proton Pump Inhibitor, Bismuth Based Quadruple Therapy, Treatment
- Trial name
- NCT07165444
- Testing
- Potassium-Competitive Acid Blocker, Proton Pump Inhibitor
- Where
- Egypt
- Volunteers
- 320 people
- Sponsor
- Tanta University
Proton Pump Inhibitors, Human Gastrointestinal Tract
Intestinal Microbiota After PPI Treatment
This clinical study aims to investigate the effects of short-term treatment with proton pump inhibitors (PPIs) on the gut microbiota of pediatric patients.
- Conditions
- Proton Pump Inhibitors, Human Gastrointestinal Tract, Gastroesophageal Reflux Disease
- Trial name
- PPI (NCT07036627)
- Testing
- study of microbiota
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Bari
Proton Pump Inhibitor Adverse Reaction, Delirium
Delirium Related to Proton Pump Inhibitors Use
Delirium is a frequent and severe condition, especially in old adults. Its occurrence is due to a drug in 30% of cases. In 2009, the French national health authority (Haute Autorité de Santé) mentioned proton pump inhibitors…
- Conditions
- Proton Pump Inhibitor Adverse Reaction, Delirium, Hyponatremia
- Trial name
- NCT05815550
- Testing
- PPI
- Where
- France
- Volunteers
- 19,081 people
- Sponsor
- University Hospital, Caen
Proton Pump Inhibitors, Deprescribing
RAK-PRIDE: Optimizing Proton Pump Inhibitor Use Through Education and Intervention
The goal of this study is to determine if a pharmacist-led educational intervention can reduce the inappropriate use of proton pump inhibitors (PPIs) among adult patients (≥18 years) with potentially inappropriate PPI…
- Conditions
- Proton Pump Inhibitors, Deprescribing, Inappropriate Use
- Trial name
- NCT06858384
- Testing
- Control (Standard treatment), Pharmacist-Led Educational Intervention
- Where
- United Arab Emirates
- Volunteers
- 479 people
- Sponsor
- RAK Medical and Health Sciences University
Vonoprazan, Proton Pump Inhibitor
Therapeutic Effect of Vonoprazan Versus Dexlansoprazole in Treatment of Gastroesophageal Reflux Disease
Gastroenterologists are often hesitated about whether to use the well known PPI in treatment of GERD or the usage of new H/K ATPase inhibitors so its highly needed to test the benefit of each class in Egyptian population to help…
- Conditions
- Vonoprazan, Proton Pump Inhibitor, Gastroesophageal Reflux Disease
- Trial name
- NCT06778395
- Testing
- Dexlansoprazole 60 mg, Vonoprazan 20 mg bid
- Where
- Egypt
- Volunteers
- 136 people
- Sponsor
- Ayman Magd Eldin Mohammad Sadek
Gastric Lesion, Proton Pump Inhibitor Adverse Reaction
Lactobacillus Reuteri Strain Combination in Children Treated With PPI
Probiotics might be of help in preventing dysbiosis and emergence of SIBO. Gastrus consisted of a mixture of two human strains of L.
- Conditions
- Gastric Lesion, Proton Pump Inhibitor Adverse Reaction, Probiotic
- Trial name
- NCT05484128
- Testing
- Gastrus
- Where
- Italy
- Volunteers
- 172 people
- Sponsor
- University of Bari
Proton Pump Inhibitors
Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program
Proton pump inhibitors (PPIs) are medications used to treat acid-related stomach disorders, such as chronic heartburn. These medications are widely used by Veterans, with over 11 million 30-day prescriptions being filled each…
- Trial name
- RaPPID (NCT03719170)
- Testing
- PPI De-prescribing Program
- Where
- 4 sites in United States
- Volunteers
- 220,306 people
- Sponsor
- VA Office of Research and Development
Proton Pump Inhibitor Adverse Reaction, Liver Cirrhosis
Proton Pump Inhibitors in Cirrhotic Patients
Proton pump inhibitors (PPIs) inappropriate use, in patients with cirrhosis, presents a significant clinical challenge. This study evaluates overprescription and misuse of PPIs in cirrhotic patients.
- Trial name
- NCT06384443
- Where
- Egypt
- Volunteers
- 1,000 people
- Sponsor
- National Liver Institute, Egypt
Proton Pump Inhibitors, Deprescription
Efficacy of a Multi-faceted Intervention to Deprescribe Proton Pump Inhibitors (PPI) in Primary Care: a Population-based, Pragmatic, Cluster-randomized Controlled Trial.
Deprescribing is defined as "the process of withdrawal of an inappropriate medication, supervised by a health care professional with the goal of managing the polypharmacy and improving outcomes".
- Trial name
- DeprescrIPP (NCT04255823)
- Testing
- General practitioner and Patient receive informations related to PPI deprescribing., Only General practitioner receive informations related to PPI deprescribing.
- Where
- France
- Volunteers
- 34,000 people
- Sponsor
- Nantes University Hospital
Proton Pump Inhibitors, Deprescription
Efficacy of a Multi-faceted Intervention Combining an Educational Outreach Visit to General Practitioners and Patient Education Material to Deprescribe Proton Pump Inhibitors (PPI): a Population-based, Pragmatic, Cluster-randomized Controlled Trial
Deprescribing is defined as "the process of withdrawal of an inappropriate medication, supervised by a health care professional with the goal of managing the polypharmacy and improving outcomes".
- Trial name
- DeprescrIPPDAM (NCT04513834)
- Testing
- GP will receive the educational outreach visit by a DAM (healthcare representative)., Patient education material on PPI deprescribing will be sent to the patients
- Where
- France
- Volunteers
- 25,000 people
- Sponsor
- Nantes University Hospital
Proton Pump Inhibitor, Primary Care
Proton Pump Inhibitors (PPI): a Study to Improve Appropriate Prescriptions in the Elderly
Proton Pump Inhibitors(PPIs) are the leading evidence-based therapy for upper gastrointestinal disorders and prevention of antiplatelet or non-steroidal anti-inflammatory drugs induced ulcer.
- Trial name
- LAPTOP-PPI (NCT04637750)
- Testing
- Educational intervention
- Where
- 3 sites in Italy
- Volunteers
- 800 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Proton Pump Inhibitor Adverse Reaction
Is Long-Term Proton Pump Inhibitor Use a Cause of Leaky Gut Syndrome
Our study aims to investigate the effect of bacterial overgrowth induced by long-term PPI use on zonulin levels.
- Trial name
- NCT06268834
- Testing
- Blood for zonulin level was drawn from the group.
- Where
- Turkey (Türkiye)
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Proton Pump Inhibitor, Inappropriate Drug Use
Patient Journey Application for Discontinuing Inappropriate PPI Use: a Randomized Controlled Trial
Rationale/objective: This study hypothesizes that offering patient-tailored and dosed information on PPI discontinuation in patients with inappropriate chronic PPI use will result in an increased discontinuation rate when…
- Conditions
- Proton Pump Inhibitor, Inappropriate Drug Use, Discontinuation, E-health
- Trial name
- SUPPORT (NCT05348252)
- Testing
- Patient Journey App, Information folder
- Where
- Netherlands
- Volunteers
- 163 people
- Sponsor
- Radboud University Medical Center
Proton Pump Inhibitor, Acute Kidney Injury
Risk Factors and Machine Learning Model for Proton Pump Inhibitor Related Acute Kidney Injury
Recent evidence concerns acute kidney injury (AKI) following proton pump inhibitor (PPI) application. Few actual studies have compared the incidence, risk factors, and predictive models of AKI associated with PPI.
- Trial name
- NCT05533619
- Testing
- Proton pump inhibitor
- Where
- China
- Volunteers
- 30,000 people
- Sponsor
- Qianfoshan Hospital
Upper Gastrointestinal Bleeding, Proton Pump Inhibitors
The Effect of Using Preendoscopic Proton Pump Inhibitors in Upper Gastrointestinal System Bleeding on Patient Prognosis
In this study, we aimed to investigate the effectiveness of ppi use in upper gastrointestinal bleeding in patients over the age of 18 who underwent endoscopy on mortality, length of hospital stay, rebleeding, and cost.
- Trial name
- NCT05467358
- Where
- Turkey (Türkiye)
- Volunteers
- 1,100 people
- Sponsor
- Ankara City Hospital Bilkent
Proton Pump Inhibitor
Evaluation of the Long-term Tolerance of Proton Pump Inhibitor (PPI) Discontinuation in Geriatric Patients Treated With Long-term Therapy Without a Recognized Indication
Proton pump inhibitors (PPIs) are widely prescribed in France as anti-ulcer drugs. The indications currently approved in France, with variations according to molecules, are as follows: eradication of Helicobacter pylori, active…
- Trial name
- EGERIPP 2 (NCT03980899)
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Vonoprazan, Helicobacter Pylori Infection
A RCT of the Efficacy of Vonoprazan 20mg QD in the Treatment of Helicobacter Pylori Infection
The treatment of helicobacter pylori is very important. The routine treatment is quadruple therapy. In recent years, double therapy has appeared and the curative effect is fair.
- Conditions
- Vonoprazan, Helicobacter Pylori Infection, Proton Pump Inhibitor
- Trial name
- VATH-1 (NCT05590286)
- Testing
- Vonoprazan Tablets, Amoxicillin Capsules, Esomeprazole
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- First People's Hospital of Hangzhou